Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of buccal desamino-
oxytocin
(
CAO
) upon uterine contractility was studied in pregnant women at term by recording the amniotic pressure. The DAO increased uterine activity and the intensity and frequency of the contractions; basal pressure did not vary. The time required to reach the maximum effect ranged between 57 and 106 minutes, whereas the time elapsed between the administration of the first tablet and the beginning of the increase of uterine activity ranged between 13 and 96 minutes. An inverse linear correlation between the percentage increase of uterine activity and the spontaneous uterine activity was observed. Ninety minutes after the suppression of DAO uterine activity remained above basal levels; uterine activity after DAO was found to be in direct linear correlation with stabilized utertine activity during DAO.
...
PMID:Latent period, time to reach maximum effect, and disappearance of uterine contractility induced by desamino-oxytocin. 111 85
The binding of 3H-
oxytocin
(3H-OT) and 3H-arginine-vasopressin (3H-AVP) and the displacement from binding sites by four
oxytocin
analogues were studied in myometrial membrane preparations from full-term pregnant women. Specific 3H-OT binding was saturable with a maximal binding capacity of 76.1 fmol/mg DNA, and a dissociation constant of 0.5 pM. Corresponding values regarding 3H-AVP was 148.6 fmol/mg DNA and 0.7 pM. The
oxytocin
analogues tested demonstrated a high specific binding to the OT and AVP receptor sites; in fact, the affinity of the analogues to the 3H-AVP binding sites was higher than to the 3H-OT binding sites. The order of potency between the analogues was CAU greater than CAM greater than CAP greater than
CAO
and CAP greater than CAU greater than
CAO
greater than CAM for the OT and AVP binding sites, respectively. The displacement of
oxytocin
and arginine-vasopressin, respectively, from the myometrial receptor sites indicate partly separate binding sites for
oxytocin
and AVP and might implicate that AVP can be of importance in regulating myometrial activity in pregnancy. The results on
oxytocin
analogues imply that other pharmacological tests must be performed for quantification of the relaxing effects on the uterus and to determine the optimal analogue for clinical trials in preterm labor and dysmenorrhoea.
...
PMID:Binding of four oxytocin analogues to myometrial oxytocin and arginine-vasopressin binding sites in pregnant women. 216 84